Gastroenteropancreatic neuroendocrine tumour disease

• Study to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients with Grade 1 and Grade 2 advanced GEP-NET (NETTER-3) Recruiting
  2024-518325-15-00 5 2025-09-08 "Gastroenteropancreatic neuroendocrine tumor (GEP-NET)"
• Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects wi … Recruiting
  2023-509334-19-00 5 2024-10-17 "gastro-enteropancreatic neuroendocrine tumors (GEP-NETs)"
• Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients (SAUNA trial) Recruiting
  2022-502703-30-00 6 2023-06-28 "neuroendocrine tumours"
• Lutetium (177Lu) Edotreotide versus Best Standard of Care in Well-differentiated Aggressive Grade 2 and Grade 3 Gastroenteropancreatic Neuro … Recruitment ended
  2024-510812-64-00 5 2021-09-30 "Well-differentiated Aggressive Grade 2 and Grade 3, Somatost"
• A trial to assess efficacy and safety of octreotide subcutaneous depot in patients with GEP-NET Recruitment ended
  2023-508723-12-00 5 2021-09-27 "gastroenteropancreatic neuroendocrine tumors"
• Study to evaluate safety and dosimetry of Lutathera in adolescent patients with GEP-NETs and PPGLs. Recruitment ended
  2023-507444-37-00 4 2021-04-21 "somatostatin receptor positive gastroenteropancreatic neuroe"
• A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in combination with best supportive … Recruitment ended
  2023-507443-10-00 5 2019-11-04 "Patients with somatostatin receptor positive, well-different"
• Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE) Recruitment ended
  2023-510444-21-00 5 2017-11-24 "Neuroendocrine tumours of gastroenteric or pancreatic origin"
• IMMUNORARE5 : A national platform of 5 academic phase II trials coordinated by Lyon university hospital to assess the safety and the efficac … Halted
  2024-517254-99-00 4 2025-09-16 "The patients enrolled in IMMUNORARE will be adult patients w"

Showing 1–9 of 9 trials